Form 4 Filing for Castle Biosciences Inc.

Kristen M. Oelschlager, Chief Operating Officer of Castle Biosciences Inc., reported several transactions on September 1, 2026. She acquired 4,152 shares of Common Stock through the exercise of stock options at a price of $3.38 per share, increasing her post-transaction shares to 17,508. Additionally, she disposed of 3,952 shares at a weighted-average price of $33.36 and 200 shares at $34.02. These transactions were conducted under a Rule 10b5-1 plan. Oelschlager also holds 72,649 shares of Common Stock indirectly through The Fritz Shorter Trust, of which she and her spouse are trustees and beneficiaries. The filing also notes the acquisition of 68 shares under the company's employee stock purchase plan.